The authors wrote in the article that, according to the researchers, it seems that the product is safe. After its administration, antibodies were said to have formed in all test participants. However, the authors also acknowledge that these people were followed for only 42 days, that the sample was small, and no placebo or control vaccine was used.
–
The safety of the substance was tested only on men and the participants were mainly people between the ages of twenty and thirty. Therefore, it is not possible to say how the substance will affect older people who are more at risk of coronavirus complications.
–
Alexander Gincburg, who heads Nikolai Gamaleji’s Institute for Epidemiological and Microbiological Research, which is developing the substance with the Ministry of Defense, told reporters that the vaccine produces a “sufficient” immune response. “We are ready to confirm the protective effect of this vaccine for two years, maybe longer,” Gincburg said, but without substantiating his claim, the AP warned.
–
An article in the Lancet magazine states that the tests were performed in two Russian hospitals on healthy adults aged 18 to 60 years. Once registered, they were required to remain in isolation. They remained in the hospital for the first 28 days after vaccination. According to the article, 76 people were tested in June and July, 100 percent of whom developed antibodies to coronavirus and none of them had serious side effects.
–
According to Reuters, Russia approved a two-dose vaccine for home use in August, but at that time did not publish the results of testing or start testing on a large sample of people.
–
“Two 42-day trials each included 38 healthy adults, no serious side effects, and the vaccine was confirmed to produce antibodies. To determine whether a substance is safe in the long term and whether it is effective in preventing covid-19 infection, a broader, long-term testing, including a placebo comparison, is needed, ”the article reads.
–
According to Reuters, foreign experts warn against the use of this substance until further and internationally recognized testing and verification steps are carried out.
–
However, the head of the Russian direct investment fund, Kirill Dmitrijev, said that by publishing the results of the first studies, Russia “has answered all the questions asked by the West in the last three weeks in order to damage the reputation of the Russian vaccine.” “Now we will start asking about some western vaccines,” he added.
–
He added that a wider test began last week, in which 3,000 people have already signed up and whose first results are expected in October or November. Minister of Health Mikhail Muraško announced that vaccination in Russia will begin in November or December, focusing on high-risk groups of people. According to Gincburg, it will take nine to twelve months to vaccinate most citizens.
—
